Lung Cancer

Kristen Neumann, DNP, FNP-C, emphasizes the importance of early assessment and potential dose reductions or holds when patients on treatment for EGFR-mutated non-small cell lung cancer show adverse effects, while Misako Nagasaka, MD, PhD, stresses the need for accurate symptom history and supporting lab work to ensure patient safety.

Kristen Neumann, DNP, FNP-C, and Misako Nagasaka, MD, PhD, discuss the importance of patient education on diarrhea as a side effect of EGFR-mutated non-small cell lung cancer treatment, emphasizing dietary considerations and the use of over-the-counter remedies.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, a family nurse practitioner with 30 years of experience in oncology, discuss EGFR-mutated non-small cell lung cancer, the available treatment options, and common side effects such as rash, emphasizing patient education and proactive management for side effects.

Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.

A brief review of novel EGFR TKIs that may have stronger CNS penetration in patients with non–small cell lung cancer and brain metastases.

Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.

Joshua Sabari, MD, and Misako Nagasaka, MD, reflect on clinical trial data and experience with mobocertinib in patients with EGFR Exon20+ non–small cell lung cancer.

Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.

Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.

The accepted new drug application is for Pemrydi RTU, a ready-to-use injectable that requires no reconstitution, dilution, or refrigeration.

Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy.

SynKIR-110, which received fast track designation from the FDA, is currently under investigation as treatment for patients with mesothelioma in the phase 1 STAR-101 trial.

The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

“Upon activating a fluorescent lamp, the cancer tissue glows very brightly, like stars against a black sky, and enables us to see exactly where the tumor tissue was.”

Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.

Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung cancer and PD-L1 expression.

Dr. Nabil Rizk, Chief of Thoracic Surgery on increasing participation and accessibility of lung cancer screening.

In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.

Closing out their review of the second patient scenario, panelists define treatment options for NSCLC with both EGFR mutation and PD-L1 expression.

Expert oncologists consider how they would approach molecular testing in a 73-year-old Asian woman diagnosed with advanced non–small cell lung cancer.

“Opportunities to escalate therapies that work well in stage IV into what we consider a more curative setting...are exactly what we need to be looking for.” –Mark A. Socinski, MD

Findings from the phase 3 ADURA trial indicated that patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC) experienced a promising reduction in risk of disease recurrence or death following treatment with adjuvant osimertinib.